Phaseline

Companies › Radiopharm Theranostics

Radiopharm Theranostics: clinical trials, targets and expected readouts

4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RAD101
18F-labeled fibroblast activation protein inhibitor (FAPI) PET imaging agent
–Phase 2Brain Metastases From Solid Tumors–
177Lu-BetaBart
Lutetium-177 labeled anti-B7-H3 monoclonal antibody
B7H3Phase 1Castration-Resistant Prostate Cancer (CRPC)Dec 2027
161Tb-RAD402
Radiolabeled anti-KLK3 monoclonal antibody targeting free prostate-specific antigen
KLK3Phase 1Castration-resistant Prostate CancerNov 2028
RAD301 ([68Ga]-RAD301)
Radiopharmaceutical diagnostic imaging agent
–Phase 1Healthy Volunteers–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06777433RAD101Phase 2Brain Metastases From Solid TumorsOncologyApr 2026
NCT05799274RAD301 ([68Ga]-RAD301)Phase 1Healthy VolunteersOncologySep 2026
NCT07189871177Lu-BetaBartPhase 1Castration-Resistant Prostate Cancer (CRPC)OncologyDec 2027
NCT07259213161Tb-RAD402Phase 1Castration-resistant Prostate CancerOncologyNov 2028

From the company's SEC filings

Cash of $29m on 2025-06-30; operating cash outflow about $37m a year; runway about 10 months at that burn, to Apr 2026

Targets

KLK3 (1) B7H3 (1)

Companies with the same targets

BioNTech SE Hansoh BioMedical R&D Company Daiichi Sankyo Qilu Pharmaceutical IDEAYA Biosciences MediLink Therapeutics (Suzhou) CSPC Megalith Biopharmaceutical Phrontline Biopharma Aktis Oncology NEOK Bio

Companies built like this

Innate Pharma Processa Pharmaceuticals Moleculin Biotech Tyra Biosciences Cellectar Biosciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.